Any current/future capex/capital investment/strategic investment?

No major new capex projects are currently planned. Normal maintenance capex is expected in the range of INR 8 crores to INR 10 crores annually. No new products are planned that would require additional capital expenditure. The company will invest INR 77.5 crores to acquire the balance 34.44% stake in Kinam Engineering Industries, increasing their holding to 70%. This payment will be made through share issuance, so there is no cash outflow. The INR 230 crores recorded represents the value of 100% purchase of Kinam's property, plant, and equipment; no additional capex for plant and machinery pur

Future growth expectations in sales/revenue/volumes?

The company anticipates growth driven by strong order books and pipeline, especially from the pharma and USA markets. Introduction of Thaletec products in India has been positive, with confirmed orders and good initial response, opening newer opportunities without cannibalizing existing markets. The API pharma segment's share, currently around 40%, is expected to increase over the next few years, possibly returning towards historical levels of 55-60%. The second half of the financial year generally contributes 55-60% of revenues, with expectations to catch up on deferred orders from first half

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects steady revenue growth aided by the recent acquisition of Kinam Engineering Industries, expanding the product portfolio and incorporating new technology. Filtration, drying, and other equipment segments grew 22.2% YoY, with plans for normal maintenance capex of INR 8-10 crores annually, indicating stable expansion. Thaletec reactors launch in India has been received positively, with confirmed orders contributing to revenue and expectations of sustaining EBITDA margins of 16% to 18%. The pharmaceutical (API) sector share, currently at ~40%, is expected to grow in coming years

Current/ Expected Orderbook/ Pending Orders?

Current order book provides about five months of visibility for the India business. Thaletec Germany business has a visibility of 9 to 10 months. The business in the USA is described as encouraging with a strong order pipeline. The company is experiencing a varied market: agrochemical segment is muted with deferred orders, specialty chemicals and pharmaceutical sectors showing stronger order flows. Overall, the order book reflects resilience and a strong pipeline of inquiries, especially from pharma sectors. Order book composition and demand are evolving, with pharma expected to increase its s

HLE Glascoat LtdQ2 FY24Industrial Manufacturing

HLE Glascoat Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹423.8P/E: 74.9Market Cap: ₹2.9K CrSector: Industrial Manufacturing

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Capex

0 of 5 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company anticipates growth driven by strong order books and pipeline, especially from the pharma and USA markets.
Introduction of Thaletec products in India has been positive, with confirmed orders and good initial response, opening newer opportunities without cannibalizing existing markets.
The API pharma segment's share, currently around 40%, is expected to increase over the next few years, possibly returning towards historical levels of 55-60%.
The second half of the financial year generally contributes 55-60% of revenues, with expectations to catch up on deferred orders from first half.
No major new capex projects planned for FY25; focus on maintaining and leveraging existing capacities.
Margins in glassline business expected to normalize at 16-18% long-term sustainable levels, supporting revenue growth in a normalized market environment.

Margin guidance

Category 3

The company expects steady revenue growth aided by the recent acquisition of Kinam Engineering Industries, expanding the product portfolio and incorporating new technology.
Filtration, drying, and other equipment segments grew 22.2% YoY, with plans for normal maintenance capex of INR 8-10 crores annually, indicating stable expansion.
Thaletec reactors launch in India has been received positively, with confirmed orders contributing to revenue and expectations of sustaining EBITDA margins of 16% to 18%.
The pharmaceutical (API) sector share, currently at ~40%, is expected to grow in coming years, supporting future order book growth.
Domestic glassline business margins are projected to stabilize around 16%-18%, down from volatile past highs but sustainable.
Operating leverage from higher revenue will help improve margins.
Promoters plan to maintain a healthy stake, indicating confidence in long-term growth.
Overall, the company anticipates resilient earnings growth driven by product diversification, market expansion, and improved operational efficiencies.

See what HLE Glascoat Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

- There is no indication of any current or planned reduction of promoter stakes beyond the recent strategic investor inclusion, which was aimed at bringing a high-quality investor without reducing promoter holdings significantly. - There is no mention of any new fundraising through equity in the transcript; the focus was on issuing shares to erstwhile promoters of Kinam as part of acquisition consideration, not new equity raise. - Regarding debt, the company has highlighted significant cash flow available for debt repayment in the next year, implying a focus on deleveraging rather than raising new debt. - Capex plans for FY25 are limited to normal maintenance capex (~INR 8-10 crores), with no major new investments requiring additional fundraising. Overall, no clear plans for fresh fundraising through either debt or equity were disclosed in the call.

Order book

Current order book provides about five months of visibility for the India business.
Thaletec Germany business has a visibility of 9 to 10 months.
The business in the USA is described as encouraging with a strong order pipeline.
The company is experiencing a varied market: agrochemical segment is muted with deferred orders, specialty chemicals and pharmaceutical sectors showing stronger order flows.
Overall, the order book reflects resilience and a strong pipeline of inquiries, especially from pharma sectors.
Order book composition and demand are evolving, with pharma expected to increase its share over time.
The company continues to manufacture based on confirmed orders, leading to inventory fluctuations aligned with order flow.

See what HLE Glascoat Ltd management said on order book — free account, 30 seconds.

Capex plans

No major new capex projects are currently planned.
Normal maintenance capex is expected in the range of INR 8 crores to INR 10 crores annually.
No new products are planned that would require additional capital expenditure.
The company will invest INR 77.5 crores to acquire the balance 34.44% stake in Kinam Engineering Industries, increasing their holding to 70%. This payment will be made through share issuance, so there is no cash outflow.
The INR 230 crores recorded represents the value of 100% purchase of Kinam's property, plant, and equipment; no additional capex for plant and machinery purchase is anticipated.
Overall, capital investments focus on strategic acquisitions and maintenance rather than expansion or new product development.

Track HLE Glascoat Ltd — get its next earnings analysis in your feed

How does HLE Glascoat Ltd rank vs peers in Industrial Manufacturing?

Pro feature

ThisHLE Glascoat Ltd

Rev 3Mar 3

See where HLE Glascoat Ltd sits in Industrial ManufacturingSee which companies these are, and every other name in the sector.Open rankings

How does HLE Glascoat Ltd rank in Industrial Manufacturing?

Compare HLE Glascoat Ltd against every Industrial Manufacturing company (Q2 FY24) on revenue, margins and earnings-call signals.

View Industrial Manufacturing leaderboard →

What HLE Glascoat Ltd's management said in earlier quarters

Others in Industrial Manufacturing this season

Honeywell Automation India Ltd (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹12,239 million (Page 4) . Key results statement takeaways from Honeywell Automation India Ltd
Raymond Ltd (Q2 FY27)
Consolidated revenue for Q2 FY27: ₹683 Cr, a 21% YoY increase (Page 13, 15). Key investor presentation takeaways from Raymond Ltd's Q2 FY27 investor presentatio
Mazagon Dock Shipbuilders Ltd (Q2 FY27)
Revenue from Operations for Q2 2026-27: ₹2,446 Cr (up from ₹2,929 Cr in Q2 2025-26 — a decrease year-on-year) . Key investor presentation takeaways from Mazagon
Macpower CNC Machines Ltd (Q2 FY27)
Year-on-year (YoY) growth for Q2 FY27 revenue: +40.4% . Key investor presentation takeaways from Macpower CNC Machines Ltd's Q2 FY27 investor presentation — and

Compare:vs Mazagon Dock Shipbuilders Ltd vs Indo-MIM Ltd vs Aditya Infotech Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

HLE Glascoat Ltd Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does HLE Glascoat Ltd rank in Industrial Manufacturing?

Continue your research

What HLE Glascoat Ltd's management said in earlier quarters

Others in Industrial Manufacturing this season